Berndt Modig Sells 2,292 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) CEO Berndt Modig sold 2,292 shares of Pharvaris stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $29.22, for a total value of $66,972.24. Following the transaction, the chief executive officer directly owned 137,500 shares in the company, valued at approximately $4,017,750. This trade represents a 1.64% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Berndt Modig also recently made the following trade(s):

• On Thursday, April 16th, Berndt Modig sold 2,292 shares of Pharvaris stock. The stock was sold at an average price of $28.60, for a total value of $65,551.20.
• On Thursday, April 9th, Berndt Modig sold 23,333 shares of Pharvaris stock. The stock was sold at an average price of $27.74, for a total value of $647,257.42.

Pharvaris Stock Up 3.7%

PHVS opened at $30.54 on Friday. The firm has a market cap of $2.00 billion, a price-to-earnings ratio of -9.60 and a beta of -2.34. Pharvaris N.V. has a 52 week low of $15.46 and a 52 week high of $33.33. The business’s 50 day moving average is $28.41 and its two-hundred day moving average is $26.79.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.82) by $0.12. Equities analysts expect that Pharvaris N.V. will post -3.25 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

PHVS has been the topic of several analyst reports. UBS Group set a $74.00 target price on Pharvaris in a research note on Wednesday, May 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a research note on Tuesday, April 21st. HC Wainwright restated a “buy” rating and issued a $60.00 price target on shares of Pharvaris in a research note on Tuesday, March 3rd. Citigroup restated a “buy” rating on shares of Pharvaris in a research report on Wednesday, April 15th. Finally, Wall Street Zen upgraded Pharvaris from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Pharvaris presently has a consensus rating of “Moderate Buy” and a consensus price target of $49.18.

Hedge Funds Weigh In On Pharvaris

Several institutional investors have recently added to or reduced their stakes in the business. California State Teachers Retirement System increased its stake in Pharvaris by 2.2% in the fourth quarter. California State Teachers Retirement System now owns 23,982 shares of the company’s stock valued at $666,000 after purchasing an additional 520 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in Pharvaris in the fourth quarter valued at $35,000. Public Employees Retirement System of Ohio increased its stake in Pharvaris by 20.7% in the fourth quarter. Public Employees Retirement System of Ohio now owns 7,569 shares of the company’s stock valued at $210,000 after purchasing an additional 1,300 shares during the last quarter. Finally, Legal & General Group Plc increased its stake in Pharvaris by 17.2% in the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after purchasing an additional 1,695 shares during the last quarter.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.